Shilpa Medicare ties with Cadila Healthcare for production of ZyCoV-D vaccine

ZyCov-D is the first DNA plasmid vaccine in the world for human use developed indigenously by CHL against the Covid-19 virus.

Sep 24, 2021 02:09 IST India Infoline News Service

Shilpa Medicare Limited. via its wholly owned subsidiary, Shilpa Biologicals Pvt Ltd (SBPL), has entered into a definitive agreement with Cadila Healthcare Ltd (CHL) for production-supply of the ZyCoV-D vaccine drug substance from its integrated Biologics R&D cum Manufacturing center at Dharwad, Karnataka.

The targeted production of the ZyCoV-D vaccine from this facility will be mutually agreed upon by both parties.

ZyCov-D is the first DNA plasmid vaccine in the world for human use developed indigenously by CHL against the Covid-19 virus. It is also the first COVID-19 vaccine for adolescents in the 12-18 age group, besides the adult population and is a needle-free vaccine administered using

The PharmaJet a needle free applicator, which ensures painless intradermal vaccine delivery.

CHL will transfer the ZyCoV-D technology to SBPL. Under the agreement, SBPL will be responsible for manufacture of the Drug substance of the vaccine, while CHL is responsible for filling/packaging/distribution/marketing of the vaccine in its marketing territories.

The biologics business has been identified as a strategic growth engine by SML and it has made significant investments in setting up a high end, flexible biologics facility in SBPL.

This facility at Dharwad would cater to the requirements of the fast-growing biologics field, that include the DNA vaccine, adenoviral, subunit vaccines, monoclonal antibodies & fusion proteins.

At around 2:39 PM, Shilpa Medicare was trading at Rs571 per piece down by 0.19% while Cadila Healthcare was also tumbling by 0.33% at 565.05 per piece.

Related Story

Open Free Demat Account (Rs699)
Open ZERO Brokerage Demat Account

  • 0

    Delivery Brokerage for Lifetime

  • 20

    Per order for Intraday, F&O, Currency & Commodity